Bovine Enzootic Leukosis (BLV)

Bovine enzootic leukosis (BLV) is a chronic, contagious, lymphoproliferative disease of cattle caused by the bovine leukemia virus, a retrovirus of the genus Deltaretrovirus. The disease is characterized by persistent lymphocytosis, lymph node enlargement, and the development of multicentric lymphosarcoma in a minority of infected animals. BLV infection is endemic in many dairy herds worldwide, with significant economic impact due to reduced milk production, increased culling, and trade restrictions. The disease primarily affects adult cattle, with a long incubation period of 1 to 5 years. Clinical signs are often absent in the majority of infected animals, which serve as reservoirs for transmission. The economic burden includes losses from premature culling, decreased reproductive efficiency, and increased susceptibility to other diseases. BLV is a notifiable disease in some countries, and control programs focus on identification and segregation of infected animals, biosecurity measures, and in some cases, test-and-cull strategies.

The causative agent is the bovine leukemia virus (BLV), an enveloped, single-stranded RNA virus belonging to the family Retroviridae, genus Deltaretrovirus. The virus integrates a DNA provirus into the host genome, leading to lifelong infection. BLV is closely related to human T-lymphotropic virus (HTLV). The virus primarily infects B lymphocytes, causing polyclonal expansion and, in some cases, monoclonal transformation leading to lymphosarcoma. Transmission occurs horizontally through transfer of infected lymphocytes, primarily via iatrogenic routes such as contaminated needles, surgical instruments, dehorning and tattooing equipment, and rectal palpation sleeves. Colostrum and milk can also contain infected cells, but transmission via these routes is less efficient. Vertical transmission in utero is rare but possible. Insect vectors, particularly tabanid flies, may contribute to mechanical transmission in some regions. The virus is fragile and does not survive long outside the host, requiring direct cell-to-cell contact for efficient spread.

BLV infection is distributed worldwide, with higher prevalence in dairy cattle compared to beef cattle. In the United States, herd-level prevalence exceeds 90% in some dairy regions, while individual animal prevalence averages around 40%. The disease is more common in intensive dairy production systems, with risk factors including high stocking density, frequent use of needles and surgical instruments, and management practices that increase contact between animals. Age is a significant factor, with prevalence increasing with age due to cumulative exposure. Breed susceptibility varies, with Holstein-Friesian cattle showing higher seroprevalence than Jersey or beef breeds. The economic impact is substantial, with estimated losses of $40 to $100 per cow per year due to reduced milk yield, increased culling, and decreased reproductive performance. Morbidity is low in terms of clinical disease, with only 1-5% of infected cattle developing lymphosarcoma, but mortality is high once tumors develop. The disease has a significant impact on international trade, as many countries require BLV-free status for importation of cattle and germplasm.

BLV infection begins with entry of the virus into B lymphocytes, where it integrates as a provirus into the host DNA. The virus expresses structural and regulatory proteins, including the oncoprotein Tax, which drives polyclonal proliferation of infected B cells. This results in persistent lymphocytosis, defined as an absolute lymphocyte count greater than 10,000 cells/µL in adult cattle, in approximately 30-70% of infected animals. The majority of infected cattle remain asymptomatic carriers. In a minority of animals, secondary genetic mutations and chromosomal aberrations lead to monoclonal expansion of a single transformed B cell, resulting in lymphosarcoma. Tumors can develop in various organs, including lymph nodes, abomasum, heart, uterus, and spinal cord. The pathogenesis of tumor development is not fully understood but involves dysregulation of apoptosis and cell cycle control. The clinical signs are primarily due to space-occupying effects of tumors, leading to obstruction, hemorrhage, or organ dysfunction. Immunosuppression associated with BLV infection may increase susceptibility to other infectious diseases, although this is debated.

Intrinsic risk factors include age, with older cattle more likely to be infected and develop clinical disease. Genetic susceptibility varies among breeds and individuals, with some cattle showing resistance to persistent lymphocytosis. High milk production is associated with increased risk of infection, possibly due to stress and management practices. Extrinsic factors include management practices that facilitate transmission, such as reuse of needles, improper disinfection of surgical equipment, and lack of biosecurity measures. High stocking density and co-mingling of infected and non-infected cattle increase transmission risk. Insect vectors, particularly in warm climates, may contribute to spread. Calves born to infected dams may acquire infection through ingestion of contaminated colostrum or milk, although this is less common than horizontal transmission. Stress, such as calving, transport, or concurrent disease, may increase the likelihood of progression to lymphosarcoma.

Clinical signs of BLV infection are primarily associated with the development of lymphosarcoma, which occurs in 1-5% of infected cattle. The most common presentation is multicentric lymphosarcoma, characterized by enlargement of peripheral lymph nodes (prescapular, prefemoral, parotid, and supramammary). Affected cattle may show weight loss, decreased milk production, anorexia, and lethargy. Tumors in the abomasum can cause signs of abomasal obstruction or ulceration, including abdominal distension, melena, and anemia. Cardiac involvement can lead to congestive heart failure, with signs such as jugular distension, brisket edema, and exercise intolerance. Spinal cord compression from vertebral tumors can cause ataxia, paresis, or paralysis. Uterine tumors may cause reproductive problems, including infertility or abortion. Ocular involvement is rare but can cause exophthalmos. In some cases, the disease is an incidental finding at necropsy. Persistent lymphocytosis is a common hematologic finding but is not associated with clinical signs.

Differential diagnoses for BLV-associated lymphosarcoma include other causes of lymph node enlargement, such as chronic infections (e.g., tuberculosis, actinobacillosis), and other neoplasms (e.g., adenocarcinoma). Abomasal tumors must be differentiated from other causes of abomasal obstruction, such as abomasal displacement, volvulus, or foreign body. Cardiac tumors should be distinguished from other causes of heart failure, including traumatic pericarditis, endocarditis, and cardiomyopathy. Spinal cord signs may be due to trauma, abscesses, or other neoplasms. Persistent lymphocytosis must be differentiated from other causes of leukocytosis, such as leukemias or chronic infections. Diagnostic tests, including serology for BLV antibodies, PCR for proviral DNA, and histopathology of biopsied lymph nodes, are essential for definitive diagnosis. Ultrasonography and radiography can help identify tumors in internal organs.

The diagnostic approach for BLV infection begins with herd-level screening using serological tests, such as agar gel immunodiffusion (AGID) or enzyme-linked immunosorbent assay (ELISA), to detect antibodies against BLV. Positive animals are confirmed with PCR to detect proviral DNA. For individual animals with clinical signs suggestive of lymphosarcoma, a thorough physical examination should be performed, including palpation of peripheral lymph nodes and rectal examination to detect internal masses. Hematology may reveal lymphocytosis, but this is not diagnostic. Ultrasonography of the thorax and abdomen can identify tumors in the heart, abomasum, and other organs. Fine-needle aspiration or biopsy of enlarged lymph nodes or masses can provide cytological or histopathological confirmation. In cases of abomasal obstruction, exploratory laparotomy may be necessary. At necropsy, gross and histopathological findings are diagnostic.

Hematological findings in BLV-infected cattle may include persistent lymphocytosis, with absolute lymphocyte counts exceeding 10,000 cells/µL in adult cattle. However, this is not present in all infected animals. Serum biochemistry may be normal unless organ dysfunction occurs. In cases of abomasal ulceration, anemia and hypoproteinemia may be present. Cerebrospinal fluid analysis may show lymphocytic pleocytosis if spinal tumors are present. Serological tests, including AGID and ELISA, are the primary laboratory methods for diagnosis. PCR is used to detect proviral DNA and is more sensitive than serology, especially in early infection. Histopathology of tumor tissue reveals infiltration by neoplastic lymphocytes, often with a characteristic starry-sky appearance due to tingible-body macrophages. Immunophenotyping can confirm B-cell origin.

Ultrasonography is a valuable tool for detecting tumors in internal organs. In the thorax, cardiac tumors may appear as hypoechoic masses within the myocardium or pericardial effusion. Abdominal ultrasonography can identify abomasal wall thickening or masses, as well as hepatomegaly or splenomegaly. Radiography is less commonly used but may reveal mediastinal masses or vertebral lesions. Computed tomography (CT) and magnetic resonance imaging (MRI) are not routinely used in cattle but can provide detailed imaging of tumors. Endoscopy can be used to visualize abomasal tumors, but is rarely performed in practice.

Cytological examination of fine-needle aspirates from enlarged lymph nodes or masses typically reveals a monomorphic population of large lymphoid cells with high nuclear-to-cytoplasmic ratio, prominent nucleoli, and frequent mitotic figures. Histopathology of affected tissues shows effacement of normal architecture by neoplastic lymphocytes, which may be diffuse or nodular. The cells are typically B lymphocytes, as confirmed by immunohistochemistry. In the abomasum, tumors may cause thickening of the wall and ulceration. In the heart, tumors may infiltrate the myocardium and pericardium. The presence of multicentric tumors is characteristic. Persistent lymphocytosis is characterized by a polyclonal expansion of B cells in the peripheral blood, which can be distinguished from lymphosarcoma by flow cytometry or PCR for clonality.

There is no effective treatment for BLV infection or lymphosarcoma in cattle. Antiviral drugs used in human retroviral infections have not been shown to be effective or economically feasible in cattle. Management focuses on preventing transmission and controlling the disease at the herd level. Infected animals should be identified and either culled or segregated from non-infected animals. Strict biosecurity measures, including the use of single-use needles and proper disinfection of surgical instruments, are essential. Calves should be fed colostrum from BLV-negative dams or heat-treated colostrum to reduce the risk of transmission. In some countries, test-and-cull programs have been successful in eradicating the disease. Supportive care for animals with clinical lymphosarcoma is generally not recommended due to poor prognosis, and euthanasia is often the most humane option.

The prognosis for cattle with clinical lymphosarcoma is poor, with most animals dying within weeks to months of diagnosis. The prognosis for asymptomatic BLV-infected cattle is variable, as many remain healthy for life, but they are at risk of developing lymphosarcoma and can transmit the virus to other cattle. The economic impact of BLV infection on herd productivity is significant, with reduced milk yield and increased culling rates. Control programs that reduce the prevalence of infection can improve herd profitability. The prognosis for eradication of BLV from a herd is good if strict biosecurity and test-and-cull strategies are implemented.

For herds implementing BLV control programs, regular serological testing (e.g., every 6-12 months) is recommended to monitor prevalence and identify new infections. Infected animals should be culled or segregated. Biosecurity measures should be reviewed and reinforced. For individual animals with clinical signs, regular monitoring of tumor progression may be considered, but due to poor prognosis, euthanasia is often recommended. Herd-level monitoring of milk production and reproductive performance can help assess the economic impact of BLV.

A key pearl is that BLV infection is often subclinical, and routine testing is essential for control. A common pitfall is the reuse of needles and surgical equipment without proper disinfection, which is a major route of transmission. Another pitfall is the failure to recognize that persistent lymphocytosis is not diagnostic of lymphosarcoma, and further diagnostic testing is needed. When performing rectal palpation, using a new sleeve for each cow is crucial to prevent transmission. Colostrum from BLV-positive cows should be heat-treated or replaced with colostrum from negative cows to reduce calf infection. It is important to note that BLV is not zoonotic and poses no risk to human health.

There are no specific antiviral drugs approved for BLV in cattle. Treatment is not recommended for clinical lymphosarcoma due to poor prognosis. Supportive care may include anti-inflammatory drugs such as flunixin meglumine (1.1-2.2 mg/kg IV) for pain and inflammation, but this is palliative. Antibiotics may be indicated for secondary infections. In some research settings, immunomodulatory agents have been studied, but none are commercially available. The focus should be on prevention and control through biosecurity and management.

Numerous studies have evaluated the economic impact of BLV, with meta-analyses showing a significant reduction in milk production and increased culling risk. A landmark study by Ott et al. (2003) estimated annual losses of $40 to $100 per cow in infected herds. Research on control strategies has demonstrated that test-and-cull programs can reduce prevalence, but are costly. A study by Erskine et al. (2012) found that herd-level prevalence was associated with increased somatic cell count and mastitis incidence. The use of heat-treated colostrum has been shown to reduce transmission to calves. Current guidelines from the American Association of Bovine Practitioners (AABP) recommend biosecurity measures and testing to control BLV. There is ongoing research into vaccines, but none are commercially available.